/Scientific Advisory Board
Scientific Advisory Board2018-10-03T16:56:05+00:00
Management
Scientific Advisory Board

Scientific Advisory Board

Scott Whitcup, MD

Dr. Scott Whitcup is the Founder and CEO of Akrivista and Whitecap Biosciences, two companies focused on developing new therapies in ophthalmology and dermatology.

Previously, Dr. Whitcup was the Executive Vice President, Research and Development and Chief Scientific Officer at Allergan where he lead an organization focused on therapeutic areas including ophthalmology, CNS, urology, dermatology, medical aesthetics, anti-infectives, and surgical obesity. Before Allergan, Dr. Whitcup was the Clinical Director at The National Eye Institute at the National Institutes of Health (NIH), where he led the intramural clinical research program.

Dr. Whitcup has 17 issued and 20 pending US patents. He is a Diplomate of both the American Board of Internal Medicine and the American Board of Ophthalmology, a licensed M.D. in CA, and is on the Clinical Faculty of the Department of Ophthalmology, at the Jules Stein Eye Institute, David Geffen School of Medicine. Dr. Whitcup serves on the Board of Semnur Pharmaceuticals, Menlo Therapeutics and NightstaRx. Dr. Whitcup served on the Board of Avanir Pharmaceuticals and Questcor Pharmaceuticals.

Dr. Whitcup has a B.A. in Neurobiology and Behavior from Cornell University and an M.D from Cornell University Medical College. He completed his residency in Internal Medicine at the UCLA Medical Center, his residency in Ophthalmology at Harvard Medical School-Massachusetts Eye & Ear Infirmary, and a fellowship in Uveitis and Ocular Immunology at the National Eye Institute at the National Institutes of Health (NIH).

John Hovanesian, MD

Dr. John Hovanesian is a board certified ophthalmologist and a faculty member at the UCLA Jules Stein Eye Institute. In addition, he is an internationally recognized leader in the fields of corneal, cataract, refractive and laser surgery.

Dr. Hovanesian received his medical degree from the University of Michigan Medical School and completed his fellowship in ophthalmology at the Jules Stein Eye Institute at UCLA. . He is currently a clinician at Harvard Eye Associates and a clinical faculty at UCLA.

Dr. Hovanesian is widely regarded as the leader in pterygium disease treatment. He is the editor of the textbook “Pterygium Techniques and Technology for Surgical Success” and lead author of 2017 Pterygium “White Paper”. He is the chairman of American Academy of Ophthalmology, Anterior Segment and an editorial board member for five other eye journals. He has been honored by the American Academy of Ophthalmology and the American Society of Cataract and Refractive Surgery for his contributions to the field.

Dr Hovanesian is also the Principal Investigator for over 16 ophthalmology clinical trials. He is a member at over 20 scientific and medical advisory boards.